Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma

What this study is about

The purpose of this study is to evaluate the impact of inhaled ARO-RAGE on the late asthmatic response (LAR) following an inhaled allergen challenge in participants with mild atopic asthma.

Who can join (things the study team will check)

✅ You may be able to join if…

• Clinically stable, mild atopic asthma (FEV1 ≥70% predicted)
• Established allergy confirmed by positive skin prick test at screening
• Willing and able to perform lung function tests and other study-related procedures
• Participants of childbearing potential must consent to use a method of highly-effective contraception in addition to a condom during the study and for at least 90 days following the end of study or last investigational product administration, whichever is later

🚫 You may not be able to join if…

• Concomitant diagnosis of a clinically important pulmonary disease other than asthma
• Use of corticosteroids, immunosuppressives, or anti-inflammatory medications that interfere with inhaled challenges or inflammation, or chronic use of any other medication for treatment of allergic asthma
• History or current medical condition contraindicating methacholine challenge Note: Additional inclusion/exclusion criteria may apply per protocol.

Where this trial is running

• Research Site 1, Vancouver, British Columbia, Canada
• Research Site 2, Calgary, Canada
• Research Site 3, Edmonton, Canada
• Research Site 5, Hamilton, Canada
• Research Site 4, Saskatoon, Canada

Who to contact

Medical Monitor · 626-304-3400 · ARORAGE-2001@arrowheadpharma.com

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07241546.